Results from a secondary analysis of the ENCHANTED trial add to a pile of weak data that likely will not affect clinical practice.
Significant infarct progression can make patients ineligible for mechanical thrombectomy.
The findings support the continuation of high-intensity statin therapy after acute ischemic stroke.
Insulin-resistant patients with ischemic stroke or transient ischemic attack and a high risk of myocardial infarction or recurrent stroke are more likely to derive benefit from pioglitazone than those a lower risk.
A better understanding of characteristics of cerebral lesions may help expedite treatment and improve functional outcomes.
The investigators noted that rivaroxaban was associated with significantly reduced length of hospital stay compared with warfarin.
The findings align with current guidelines to administer IV tPA regardless of whether or not a patient with ischemic stroke is set to undergo mechanical thrombectomy.
There is some evidence that suggests intravenous thrombolysis for stroke may impair the blood-brain barrier and cause cerebral edema.
The findings may be less applicable to low-volume stroke centers who have less experience in this treatment.
Investigators found a positive association between higher childhood BMI scores and early adult ischemic stroke.
THRIVE scores not only accurately predicted good and poor outcomes in stroke patients following IVT or ET, but also the degree of ischemia following these treatments.
Despite disappointing results, tenecteplase's story in stroke treatment might not be over.
Women and patients of African-American race face an increased risk of experiencing poststroke recrudescence.
Only 16% of patients had an adequate response to conventional therapy, with patients who didn't considered "non-responders."
There are a limited number of prediction models that identify patients at risk of major bleeding after stroke or TIA.
Reduced door-to-needle times have been shown to improve outcomes after stroke.
Risk for symptomatic intracranial hemorrhage after endovascular treatment for acute ischemic stroke is significantly higher in real-world practice than rates reported by clinical trials.
No between-group differences were observed for reperfusion success and mortality, among other measures.
Intensive antiplatelet therapy appears to reduce risk of recurrence immediately after stroke, but may pose risks further out.
New research from the American Heart and American Stroke Associations found that many Americans don't know the symptoms of stroke.
The relative risk of developing ischemic stroke was increased in patients with systemic lupus erythematosus, especially within the first year after diagnosis.
Neurologists need to engage their emergency medicine colleagues to identify protocols and pathways for when to trigger appropriate neurological consultation or initiate acute stroke therapies.
Over 32% of patients were functionally independent at 90 days and 37.1% were functionally independent at 2 years.
Pulse pressure was associated with the risk for ischemic stroke in first-ever ischemic stroke patients old than 60 years.
Previous research had suggested that the benefits of IV tPA are diminished in patients weighing more than 100 kg.
Up to 20% of stroke cases in young adults occur in those with cervical artery dissection, the leading cause of stroke in this population.
Clinicians should closely monitor patients with atrial fibrillation, especially if they are female and of increasing age.
Efficacy of triple antiplatelet therapy compared with current guideline-based therapy for the prevention of recurrent stroke was evaluated in the TARDIS trial.
The results provide good evidence for the use of contact aspiration in ischemic stroke.
Delays related to the determination of treatment eligibility increased door-to-needle times by more than 30 minutes compared with patients with no delays.
Neurology Advisor Articles
- Migraine and Gastrointestinal Disorders: Elucidating an Association
- Alzheimer's Disease Risk Similar in Women and Men With APOE ε3/ε4 Genotype
- Non-Invasive Magnetic Device Approved by FDA for Migraine Tx
- Multiple Sclerosis Risk Significantly Associated With Vitamin D Deficiency
- FDA Approves Device for Tx of Chronic Pain
- Defining Unique Needs for Palliative and Hospice Care in Huntington Disease
- ENCHANTED Update: No Role for Low-Dose Alteplase After All?
- Gender Plays a Role in Autism Spectrum Disorder Recurrence Among Siblings
- Prescription, OTC Sleep Medications Often Used in Older Adults
- Medicare Boosted Restrictions on Opioids From 2006-2015